Raymond James Financial
MRKR icon

Raymond James Financial’s Marker Therapeutics MRKR Stock Holding History

Raymond James Financial’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,515
Closed -$14.6K – 6051
2025
Q2 		$14.6K Buy
+9,515
New +$12.2K ﹤0.01% 5743

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Raymond James Financial's MRKR Position: Q3 2025 in Review

Raymond James Financial sold out of Marker Therapeutics (MRKR) in Q3 2025, closing a stake of 9,515 shares — an estimated $14.6K sold.

Raymond James Financial first reported a position in MRKR in Q2 2025 and held it in 1 quarter. The position peaked at $14.6K in Q2 2025. 32 funds tracked by Wall St. Rank hold MRKR as of Q3 2025.

  • Raymond James Financial reported no remaining Marker Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 9,515 Marker Therapeutics shares in Q3 2025, an estimated $14.6K.
  • Raymond James Financial first reported a position in Marker Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Marker Therapeutics position peaked at $14.6K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.